ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own MAZE shares is N/A, representing N/A of the company's common stock.
N/A, in the last quarter, reduced its stake in MAZE by N/A restricting it's holding to - shares of worth nearly -. N/A also lessened N/A of the MAZE shares from its portfolio, reducing its holding to - shares of worth -. N/A also shunned MAZE shares holding by N/A last quarter which brought its holding to - shares worth -.
As per its latest 13F filing, N/A increased its stake in MAZE by N/A in the last quarter. The institutional holder raised its holding to - shares having worth more than -. N/A also added N/A more shares of MAZE to its portfolio, raising its holding to - shares of worth -. N/A also increased its MAZE shares holding by N/A which brought its holding to - shares worth -.
The insider with the most stakes in MAZE is N/A , N/A at the company. Additionally, MAZE stock is highly held by N/A N/A and N/A N/A among others.
Company executives, directors, and other insiders own N/A percent of Maze Therapeutics, Inc. Common Stock's stock. Within the last six months, there have been 0 transaction(s) in which MAZE insiders have sold stock, totaling 0 shares. Insiders that have sold shares include .
There have been 0 transaction(s) during the past 6-months in which Maze Therapeutics, Inc. Common Stock insiders have bought stock, totalling 0 shares
Around 0 Maze Therapeutics, Inc. Common Stock shares are held by insiders, which represents about N/A of MAZE stock.
MAZE N/A, N/A holds the largest portfolio of the company's shares. MAZE shares owned by N/A total nearly -.
N/A is the largest institutional owner in MAZE which holds - shares worth - or N/A of the total MAZE shares outstanding followed by N/A with ownership of - shares representing N/A of the MAZE ownership. N/A is the third largest stakeholder with - shares or N/A of the ownership worth more than -.
Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the MAZE is concerned, it is a stock which is not optionable.
Number of MAZE shares short is null. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.
As of today, null shares of MAZE are outstanding.
Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, MAZE has null shares in float.
Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for MAZE is null.